TABLE 2

Characteristics of studies investigating the association between platelet-to-lymphocyte ratio (PLR) on admission and adverse outcomes in acute exacerbations of chronic obstructive pulmonary disease

First author, year, countryStudy designSample sizeSettingOutcomeOR (95% CI)AUC (95% CI)Cut-offSensitivity (%)Specificity (%)Additional findings
Kumar, 2017, Australia [25]R181EDMortality1.15# (1.02–1.30)0.695 (0.551–0.840)2356374PLR in survivors versus nonsurvivors: 208±164 versus 348±228, p=0.01
Yao, 2017, China [26]R303WardMortalityNR0.639 (NR)182.6864.8658.27PLR in survivors versus nonsurvivors: 198±141 versus 273±184, p=0.004
Rahimirad, 2017, Iran [27]R174WardMortalityNR0.576 (0.465–0.686)1505946PLR in survivors versus nonsurvivors: 207±192 versus 241±224, p=0.15
Aksoy, 2018, Turkey [28]R2,727WardMortalityNRNRNRNRNRPLR in survivors versus nonsurvivors: 225 (147–354) versus 224 (123–391), p=0.75
Ergun, 2018, Turkey [29]P132ICUMortalityNRNRNRNRNRPLR in survivors versus nonsurvivors: 308±260 versus 405±414, p=0.26
Yilmaz, 2019, Turkey [32]R171ICUMortality1.004# (0.994–1.014)NRNRNRNRPLR in survivors versus nonsurvivors: 98±57 versus 128±82, p=0.021
Ardestani, 2020, Iran [33]R829NRMortality1.00# (0.99–1.01)0.56 (0.52–0.59)2135882PLR in survivors versus nonsurvivors: 153±105 versus 196±154, p=0.11
Luo, 2021, China [34]R533WardMortality3.45# (1.43–12.62)0.750 (NR)203.6076.8665.27PLR in survivors versus nonsurvivors: 212±90 versus 284±132, p<0.001
Yao, 2021, China [35]R146WardMortalityNRNRNRNRNRPLR in survivors versus nonsurvivors: 257 (160–417) versus 270 (162–408), p=0.47
Zuo, 2019, China [38]R185NRPH1.003# (0.993–1.013)0.669 (0.596–0.736)15077.253.6PLR in patients without versus with PH: 157 (123–227) versus 221 (161–291), p<0.001

AUC: area under the curve; CI: confidence interval; ED: emergency department; ICU: intensive care unit; OR: odds ratio; NR: not reported; P: prospective; PH: pulmonary hypertension; R: retrospective. #: from multivariate analysis. : median and interquartile range.